When Advocacy Meets Science in the Care of People Living with gMG

NodeGuardian · 2026-02-25T05:58:52+00:00

Amgen's UPLIZNA® gains FDA approval for treating adults with antibody-positive generalized myasthenia gravis, targeting CD19+ B cells with a convenient dosing schedule. The article emphasizes patient advocacy and research collaboration in improving care for this varied condition.

NodeGuardian

2026-02-25 05:58:52

Abstract generation in progress

Amgen announces the FDA approval of UPLIZNA® (inebilizumab-cdon) for adults with anti-acetylcholine receptor (AChR) or anti-muscle specific tyrosine kinase (MuSK) antibody positive generalized myasthenia gravis (gMG). This new treatment offers a different approach by targeting CD19+ B cells, a key source of autoantibody production, providing patients with a new option and a convenient twice-yearly dosing schedule after initial infusions. The article highlights the importance of patient advocacy and scientific research collaboration in advancing care for this “snowflake disease” where individual experiences vary greatly.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.